Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Leukemia. 2013 Jul 1;27(12):2272–2279. doi: 10.1038/leu.2013.197

Figure 2. In vitro effects of the JAK2 inhibitor TG101209 and JAK1/2 inhibitor INCB18424 on murine t(8;21) leukemia cells.

Figure 2

The AEtr leukemia cell line was treated with TG101209 or INCB18424 at the concentrations indicated for 48 hours. Relative cell numbers were determined by MTS assay (CellTiter96® AQueous One Solution Cell Proliferation Assay, Promega) and are presented as percentages of the DMSO control (A). Percentages of Annexin V-positive cells (B) and percentages of cells in the G1 phase upon treatment are also shown. Each bar represents the average with SEM of triplicate samples. Representative results from three independent experiments are shown. Statistical significance of each treatment compared with the control is indicated above each bar. Statistical significance between two different treatments is also indicated. * p < 0.05, ** p < 0.01, ‡ p < 0.001